54.51 -0.15 (-0.27%)
After hours: 5:47PM EDT
|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||54.60 - 54.67|
|52 Week Range||53.56 - 55.71|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.12%|
When fixed income investors typically think about geography, they usually focus on U.S. bonds, whether it be Treasuries or corporate debt issued by US-based firms. Flows to exchange-traded funds confirm ...
According to news reports, Japanese Prime Minister Shinzo Abe could be calling for a snap election next month to capitalize on the increased approval ratings in August.
The BOJ's (Bank of Japan’s) qualitative and quantitative easing (or QQE) programs and a negative interest rate are helping to slowly revive Japanese inflation.
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV, TASE: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal flu vaccine candidate, announced today that it has closed an underwritten public offering of 1,500,000 American Depositary Shares ("ADS"), each ADS representing forty (40) of its ordinary shares which are listed on the Tel Aviv Stock Exchange (at NIS 0.0000001 par value each), at a price to the public of $6.00 per ADS. In connection with the public offering, the underwriters exercised in full their over-allotment option to purchase an additional 166,667 shares of common stock at the public offering price, less the underwriting discount. As a result, the total public offering size was 1,666,667 shares, and the gross proceeds from the public offering were $10 million, before deducting underwriting discounts and offering expenses.
BiondVax Pharmaceuticals Ltd. (BVXV) (BVXV.TA), a clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal flu vaccine candidate, today announced that it intends to offer for sale its American Depositary Shares ("ADS"), each representing forty (40) of its ordinary shares which are listed on the Tel Aviv Stock Exchange (at NIS 0.0000001 par value each). All of the ADSs in the offering are being offered by BiondVax. The offering is subject to market conditions and there can be no assurance as to whether the offering may be completed, or as to the actual size or terms of the offering.
Europe's sovereign and corporate bonds, with high yields below 2.5%, are equally susceptible to pressure, according to Peter Boockvar, chief market analyst at The Lindsey Group based in Fairfax, VA. With the euro strengthening by 1.4% against the U.S. dollar this week, maintaining a value of 1.20, Boockvar writes in his daily morning missive today: "The strangest behavior in markets yesterday was the rip higher in the euro after European Central Bank President Mario Draghi’s press conference at the same time European sovereign bonds spiked up in price and down in yields. The euro today is holding its gains and advancing some more from yesterday’s close while European yields are rising and getting back some of what it lost yesterday after a Reuters story this morning that said: 'European Central Bank policymakers meeting on Thursday were in broad agreement that their next step will be reducing their bond purchases and discussed 4 options, 2 sources with direct knowledge of the discussion said.' They talked about to what extent to cut the monthly buys at the same time maybe extending the deadline.
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV, TASE: BVXV), developer of the universal flu vaccine candidate M-001, today announced that its Board of Directors has decided to voluntarily delist from the Tel Aviv Stock Exchange (TASE), while maintaining a continued listing on NASDAQ. Following the European Investment Bank (EIB)'s significant €20 million funding agreement, and as BiondVax progresses towards Phase 3 clinical trials and construction of its commercial mid-size manufacturing facility, the Board of Directors decided that BiondVax will focus its efforts on the international scene.
This year’s theme for the annual Jackson Hole Symposium is “Fostering a Dynamic Global Economy.”
Israel Innovation Authority Approves Additional Budget towards M-001 Flu Vaccine Development NESS ZIONA, Israel , August 14, 2017 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) (TASE: BVXV) ...
European UNISEC Co-Sponsored Trial Meets Both Primary Endpoints NESS ZIONA, Israel , July 20, 2017 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV), and the UNISEC consortium today ...
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV), developer of the Universal Flu Vaccine candidate M-001, today signed an agreement to lease approximately 1800m2 in the Jerusalem BioPark (JBP), located in the Ein Kerem Hadassah campus, next to Hadassah University Hospitals and Hebrew University's Medical School. M-001 is designed to provide protection against current and future seasonal and pandemic flu strains. Planning and design of the facility by a leading engineering company has begun, and while construction will begin soon, the agreement calls for BiondVax to begin lease payments in October 2018.
First Ascent Asset Management is a newcomer in the ETF strategist space, building two series of portfolios for advisors: one using only ETFs, the other combining ETFs with actively managed mutual funds.
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV), developer of the Universal Flu Vaccine candidate M-001, today provided a general corporate update of its activities in the first half of 2017. Ron Babecoff, BiondVax CEO, commented, "The first half of 2017 was exciting and important for BiondVax.
The European Investment Bank (EIB) and BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV), developer of the Universal Flu Vaccine candidate M-001, announced that they have entered into a €20 million (approximately $22 million) loan agreement. The event organized to mark the collaboration and the granting of the loan occurs today at the EIB Headquarters in Luxembourg, in presence of Mr. Ambroise Fayolle, EIB Vice-President responsible for innovation, and Dr. Ron Babecoff, CEO of BiondVax. Flu viruses frequently and unpredictably mutate.
By Erin Bigley April 25, 2017 More and more investors are globalizing their bond portfolios these days—with good reason. But when it comes to reducing risk, active management is essential. The French presidential election is just one reason. Bond ...
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) today announced that the Israel Investment Center, a unit of the Government of Israel's Ministry of Economy and Industry, approved a grant representing 20% of a NIS 20M budget to be utilized towards the construction of a factory for the production of Phase 3 and commercial batches of BiondVax's universal flu vaccine candidate M-001. The grant is subject to certain terms and conditions including those outlined under the Encouragement of Capital Investment Law 1959. Five completed Phase 1/2 and Phase 2 human clinical trials have shown the vaccine to be safe and immunogenic to multiple flu strains.
The 30-year Treasury yield was close to its month high as of March 10, 2017, at 3.20% in anticipation of an interest rate hike by the Fed on March 15, 2017.
NESS ZIONA, Israel, March 13, 2017 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing M-001, ...
It’s getting pretty nasty out there. The so-called ‘fee war’ is heating up to a boiling point as various fund managers and brokerage houses compete to lower expenses for investors and gain market share. Just after Schwab and Fidelity duked it out over brokerage commission costs, the latest campaign in the fee war comes from the pioneer of low-cost investing. And when John Bogle and Vanguard speak, the investment community listens.
VALLEY FORGE, Pa., Feb. 24, 2017 /PRNewswire/ -- Vanguard reported lower expense ratios today for 68 additional mutual fund and ETF shares, saving clients more than $105 million. 1 Led by notable decreases ...